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Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is among 
the most prevalent of muscular dystrophies, affecting more 
than 25,000 people in the United States alone. The disease 
typically presents in the second decade and progresses vari-
ably and unpredictably, and often asymmetrically.1 While 
virtually all muscles are affected to some degree, loss of 
function is usually most severe in facial muscles and upper 
arm and back muscles. In many patients, the hip girdle is 
severely affected, and eventual wheelchair use is common. 
There is no treatment for FSHD; therefore, there is a great 
need to discover new therapeutic options that may slow the 
advance or reverse the course of this disease.
FSHD is genetically dominant and usually caused by a 
reduction in copy number of a macrosatellite repeat at 
4q35.2 called D4Z4.2,3 The D4Z4 repeat is subject to repeat-
induced silencing, and the reduction in copy number results 
in epigenetic changes that disrupt silencing on the con-
tracted allele.4 FSHD can also be caused by mutations in the 
chromatin protein SMCHD1,5 in which case all D4Z4 
repeats become demethylated.6,7 Loss of silencing at D4Z4, 
combined with a specific allele of chr4 referred to as 4qA,8 
which provides a poly(A) signal,9 leads to accumulation of 
an RNA encoding the transcription factor DUX4.10 The 
DUX4 protein shows pathological effects on myoblasts: at 
high levels, it causes cell death,11,12 while at low levels, it 
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Abstract
Facioscapulohumeral muscular dystrophy is a genetically dominant, currently untreatable muscular dystrophy. It is caused 
by mutations that enable expression of the normally silent DUX4 gene, which encodes a pathogenic transcription factor. A 
screen based on Tet-on DUX4-induced mouse myoblast death previously uncovered compounds from a 44,000-compound 
library that protect against DUX4 toxicity. Many of those compounds acted downstream of DUX4 in an oxidative stress 
pathway. Here, we extend this screen to an additional 160,000 compounds and, using greater stringency, identify a new set 
of DUX4-protective compounds. From 640 hits, we performed secondary screens, repurchased 46 of the most desirable, 
confirmed activity, and tested each for activity against other cell death–inducing insults. The majority of these compounds 
also protected against oxidative stress. Of the 100 repurchased compounds identified through both screens, only SHC40, 
75, and 98 inhibited DUX4 target genes, but they also inhibited dox-mediated DUX4 expression. Using a target gene 
readout on the 640-compound hit set, we discovered three overlooked compounds, SHC351, 540, and 572, that inhibit 
DUX4 target gene upregulation without nonspecific effects on the Tet-on system. These novel inhibitors of DUX4 
transcriptional activity may thus act on pathways or cofactors needed by DUX4 for transcriptional activation in these cells.
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interferes with myogenesis13 and sensitizes cells to oxida-
tive stress.11 DUX4 is therefore the primary target for drug 
development in FSHD.
Mechanisms of DUX4 activity are currently actively 
being investigated. The N-terminus of DUX4 contains two 
homeodomains, which together bind to a sequence related 
to TAATCTAATCA.14,15 Several hundred DUX4 target loci 
have been identified by ChIP-seq.14,16 DUX4 acts as a pio-
neer factor at the majority of these loci, displacing nucleo-
somes to bind DNA in inaccessible chromatin, and its 
C-terminus recruits p300 and/or CBP, inducing acetylation 
of nearby histones, replacing repressive chromatin marks 
with markers of activation, leading to the expression of 
nearby genes.16
We previously developed a high-throughput screening 
assay based on the loss of viability resulting from DUX4 
expression and used it in a screen of 44,000 compounds.17 This 
screen identified 183 compounds, with the majority clustering 
into 39 chemical series. Fifty-two compounds were confirmed 
by purchasing, performing mass spectrometry, and retesting. 
Interestingly, when tested in other assays, the majority of these 
52 compounds also protected cells from another cell death–
inducing insult, namely, oxidative stress. This revealed that the 
majority of these compounds were not acting directly on 
DUX4, but rather on downstream pathways, in particular, one 
specific downstream pathway (oxidative stress) that plays a 
major role in DUX4-mediated toxicity. In order to expand the 
repertoire of DUX4-protective compounds, and to further 
explore mechanisms of protection, we have screened an addi-
tional 160,000 compounds and evaluated these against various 
cell death–inducing insults. To identify those compounds that 
might have direct effects on mechanisms of DUX4 molecular 
activity rather than on pathways downstream of DUX4, we 
have also evaluated the newly identified compounds for effects 
on transcriptional changes induced by DUX4. We report a col-
lection of new compounds that do not block DUX4-mediated 
transcription, but do inhibit toxicity, presumably by acting on 
downstream pathways. Some of these fall into chemical series 
previously identified, and some represent new chemical series. 
In addition, we describe three compounds that inhibit both tox-
icity and induction of DUX4 target gene expression.
Materials and Methods
Composition of the Library
We screened 160,000 compounds from the UT Southwestern 
Chemical Library that comprised three large compound col-
lections acquired from ChemBridge (San Diego, CA), 
ComGenex (Budapest, Hungary), and ChemDiv (San 
Diego, CA). The compounds in the library were selected to 
avoid undesirable characteristics for medicinal chemistry 
and to satisfy a relaxed version of Lipinski’s rules for good 
predicted bioavailability. The set of 160,000 compounds 
screened was selected based on diverse representation of 
chemical structure across the library.
PAINS Identification
We used the Drugs3 web server (fafdrugs3.mti.univ-paris-
diderot.fr)18 to filter pan-assay interference compounds 
(PAINS).
Repurchased Compounds
Repurchased compounds were obtained from a variety of 
sources (ChemBridge, ChemDiv, Vitas M Labs, Enamine, 
Life Chemicals, and InterBioScreen).
Cell Culture
C2C12 derivative lines were cultured in high-glucose 
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 20% fetal bovine serum (FBS; Atlanta 
Biologicals, Flowery Branch, GA), l-glutamine and sodium 
pyruvate (Gibco), and penicillin and streptomycin (P/S; 
Gibco) at 37 °C in 5% O2/5% CO2. 3T3 derivatives were 
cultured in DMEM supplemented with 10% FBS and P/S.
Luciferase Assay
Cells were plated at 1000 cells per well in 384-well plates. 
Twenty-four hours later, luciferase was induced with doxy-
cycline (dox) at 500 ng/mL. The Bright-Glo Luciferase 
Assay System (Promega, Madison, WI) was used to detect 
and quantify luminescence.
High-Throughput Screen
To minimize variation due to cell line genetic and epigenetic 
drift, we had previously generated a large frozen stock (80 
vials) of cells from a single-cell subclone of iC2C12-DUX4.17 
Cells were expanded and all vials were frozen at the same time. 
For screening, a single vial was thawed, expanded over 6 days, 
and plated in 384-well plates at a density of 1000 cells per well. 
Compounds were added 24 h later at a concentration of 5 µM 
from a 500 µM stock in DMSO. Following compound addi-
tion, dox was added at 500 ng/mL. After 24 h of exposure to 
compounds and dox, cell viability was measured using the 
ATPlite system (PerkinElmer, Waltham, MA) according to the 
manufacturer’s directions.
Cell Death Inhibition Assays
C2C12 cells were plated in 384-well plates at 625 cells/well 
in 25 µL of medium using a Biomek FX robot (Beckman, 
Indianapolis, IN) and cultured for 24 h. Cell death–inducing 
reagents were then added at the following concentrations: 
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tert-butyl-hydroperoxide (tBHP; 25 µM; Sigma), ionomy-
cin (12.5 µM; Cayman, Ann Arbor, MI), staurosporine 
(0.0125 µM; Cayman), etoposide (12.5 µM; Cayman), 
ABT-263 (12.5 µM; Selleckchem, Houston, TX), and tunic-
amycin (2.5 µM; Cayman), using an Echo 550 robot 
(LabCyte, Sunnyvale, CA). Plates were cultured for a fur-
ther 24 h, after which the plates were equilibrated to room 
temperature and medium was removed. To quantify ATP, 
CellTiter-Glo reagent (Promega) diluted (1:1) in PBS was 
added to each well and the plates were read on an Analyst 
AD 96/384 plate reader (LJL Biosystem, Sunnyvale, CA).
Dose–Response Analyses
iC2C12-DUX4 cells were exposed to compounds at various 
doses (7.44, 2.47, 0.81, 0.27, 0.09, 0.03, and 0.01 µM), fol-
lowed by dox at 250 ng/mL. Cell viability was measured 24 
h later using CellTiter-Glo.
High-Throughput qRTPCR
iC2C12-DUX4 cells were plated in 24-well plates at 4 × 104 
cells/mL. Twenty-four hours later, compounds were treated at 
a concentration of 3 µM and then dox (50 ng/mL) was added 
for 4 h. Total RNA was extracted using the ZR-96 Quick-RNA 
extraction kit according to the manufacturer’s instructions 
(Zymo Research, Irvine, CA). Reverse transcription (RT) was 
performed using the Vero cDNA synthesis kit (Thermo Fisher 
Scientific, Waltham, MA), and quantitative PCRs (qPCRs) 
were conducted using Taqman probes (Myo1g, Mm00617991_
m1; Gapdh, Mm99999915_g1; DUX4, Hs03037970_g1) 
(Applied Biosystems, Waltham, MA). mRNA expression was 
analyzed by the ΔCt method and values expressed relative to 
the expression of GAPDH.
Results
We previously developed a primary screen for inhibitors of 
DUX4 toxicity based on colorimetric detection of ATP levels 
in C2C12 myoblasts conditionally expressing DUX4 in 
response to dox.17 When dox is added to these cells, they die in 
large numbers over a 24 h period and ATP content is markedly 
reduced. Using this same screening platform, we screened 
160,000 new small molecules from the UT Southwestern 
Chemical Library. The compounds in this library represent 
structurally diverse druglike small molecules that have been 
selected to avoid medicinal chemically undesirable character-
istics, and were screened at a concentration of 5 µM.
Selection of Hits and Secondary Screening
Using a stringent z score cutoff of 5, we selected the top 640 
compounds. These were transferred from the primary 
library onto secondary screening plates, for further study. 
First, the primary screen was repeated at three concentra-
tions: 1.67, 5, and 15 µM. As expected from the relatively 
high cutoff, the majority of compounds repeated at the 
screening concentration, and were active at the other con-
centrations, although a subset lost activity at the lowest con-
centration (Fig. 1A).
Because we used the Tet-on system to express DUX4, 
some of our primary hits were expected to be indirectly pro-
tective through inhibition of the Tet-on system; that is, in 
their presence, DUX4 would not be expressed, or expressed 
at lower levels, resulting in less cytotoxicity. We therefore 
made use of a C2C12 cell line carrying a dox-inducible 
luciferase transgene.11 A small number of compounds were 
found to inhibit the dox-mediated induction of luciferase by 
the Tet-on system in these cells, and these were eliminated 
from further consideration (Fig. 1B).
Finally, we tested each compound in 3T3 cells engi-
neered to express DUX4 in response to dox (Fig. 1C). This 
revealed that approximately two-thirds of compounds that 
were active in C2C12 myoblasts were also active in 3T3 
fibroblasts.
Identification of Chemical Series within the Set 
of Confirmed Hits
Evaluating the structures in the primary hit set, together 
with those of the previous screen, we identified 46 chemical 
series. To identify “actives” within this set, we filtered using 
the secondary screening data to identify compounds that 
were active at 1.67 µM, did not inhibit Tet-on luciferase, 
and were also active in both C2C12 and 3T3 cells. From the 
640 hits, 193 compounds passed secondary screening. We 
sorted out the 193 compounds using the core definitions for 
these series, and selected at most three compounds from 
each active series. The three compounds selected were the 
best with respect to activity in iC2C12-DUX4 cells at 1.67 
µM. No compounds were selected from core series that con-
tained fewer than three representatives. In total, compounds 
from 22 of these core series were selected for follow-up 
from the two screens (Fig. 2). Seven of these series were 
unique to the current screen, 10 series had representatives 
from both screens, and 5 only had representatives from the 
first phase of screening.17
We selected at most three compounds from each series 
(those compounds with the greatest activity, i.e., that 
gave the greatest percent viability) for purchase and 
retesting. In addition, we purchased six compounds from 
the singletons class for a total of 48 compounds (Suppl. 
Table S1). Each repurchased compound was character-
ized by liquid chromatography–mass spectrometry for 
identity and purity. All compounds assayed were >90% 
pure and had parent ions that matched those of the 
expected compounds.
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Effects on Downstream Cell Death Pathways
In our previous application of this screen to a smaller library 
using a lower z-score threshold, we determined that a large 
subset of the hit compounds protected cells indirectly, by 
interfering with a cell death pathway involving oxidative 
stress. To determine to what extent compounds identified 
through this more stringent and much larger screen were 
acting at the level of downstream pathways versus acting at 
the level of DUX4 itself, we tested each purchased com-
pound for activity against six different cell death–inducing 
insults. No compounds were protective against the Bcl2 
inhibitor, ABT-263 (Fig. 3A); the broad kinase inhibitor, 
staurosporine (Fig. 3B); the Ca permeabilizer, ionomycin 
(Fig. 3D); or the endoplasmic reticulum stress inducer, 
tunicamycin (Fig. 3F). As seen in the previous screen, the 
great majority (83%) of identified compounds were protec-
tive against the oxidative stress–inducing agent tBHP (Fig. 
3E). Interestingly, the more stringent cutoff (z ≥ 5 vs z ≥ 3) 
seems to have increased the likelihood of identifying 
inhibitors in this pathway (in the previous screen, 60% of 
compounds acted in the oxidative stress pathway). The cur-
rent screen has also identified two compounds (SHC23 and 
38) that protect against etoposide, a DNA double-strand 
break-inducing compound (Fig. 3C). Interestingly, these 
two compounds are also protective against oxidative stress, 
although not against other cell death pathways.
Effects on Transcription of DUX4 Targets
Compounds that directly inhibit DUX4 would not be 
expected to protect against other cell death–inducing tox-
ins. Because both screens produced a set of compounds that 
did not have activity in these cell death–inducing insults, 
we wished to determine whether compounds in this subset 
were acting directly at the level of DUX4. A more direct 
readout of DUX4 activity is transcriptional changes in 
DUX4 target genes. We previously identified Myo1g as one 
of the most rapidly and potently upregulated mouse tar-
gets.11 We therefore tested each compound for its ability to 
Figure 1. Secondary screens. (A) Activity of the 640 hit compounds in the primary assay, at three different concentrations. The y 
axis represents the fraction of viability (ATP content) compared to cells not expressing DUX4. Note that compounds are renumbered 
in order of activity for graphs A–C. (B) Activity of the 640 hit compounds against a dox-inducible luciferase transgene. A reduction 
in luciferase activity, as seen in those compounds forming the right-hand tail of the curve, is undesirable. (C) Activity of the 640 hit 
compounds in 3T3 cells expressing DUX4 (x axis), compared to activity against C2C12 cells expressing DUX4 (y axis). Activity in both 
cell types is desirable, and those compounds showing activity in both cell types are in red.
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inhibit Myo1g upregulation by DUX4. For this work, we 
included the compounds previously identified from the 
44,000-compound library screen,17 which are here referred 
to as compounds 47–100. Three compounds were potent 
inhibitors of DUX4-induced Myo1g upregulation, and a 
number of others had a modest effect (Fig. 4A). In addition 
to upregulated target genes, there are some genes that are 
downregulated by DUX4, and we have shown previously 
that one of the strongest of these is Myod1.11 This effect is 
likely not secondary to the upregulation of a repressor of 
Myod1, as Myod1 is also a downregulated target of DUX4c, 
a variant of DUX4 lacking the C-terminal transcriptional 
activation domain, but rather represents an independent 
activity of DUX4.19 Thus, we further tested all 100 pur-
chased compounds for effects on Myod1 downregulation by 
DUX4 (Fig. 4B). One compound (SHC98) prevented both 
Myo1g activation and Myod1 repression. Two others 
(SHC40 and 75) prevented Myo1g activation only, and 
some others had weak effects. Although all of these pur-
chased hits had previously been through a secondary screen 
for effects on the Tet-on system, we also evaluated levels of 
DUX4 transcript in the presence of selected inhibitors to 
determine whether the lack of effects on DUX4 target 
genes might have the trivial explanation of blocking the 
Tet-on system. Remarkably, all three compounds that 
inhibited Myo1g expression showed reduced dox-induced 
DUX4 expression, with the most potent being SHC98 
(Fig. 4C). Thus, it is most likely that these three com-
pounds do not directly inhibit the activity of the DUX4 
protein, but rather prevent its expression by inhibiting Tet-
on-driven transcription.
Secondary Screen Based on Target Gene 
Expression Changes
Because none of the purchased compounds were able to pre-
vent gene expression changes (except for those that prevented 
Tet-on-driven DUX4 expression itself), we went back the 
640-compound hit set and performed one final secondary 
screen. In 384-well format, we tested every compound for 
its ability to inhibit DUX4-induced Myo1g upregulation. 
Compounds that prevented Myo1g upregulation (Fig. 5A) were 
then retested in conventional qRTPCR format (Fig. 5B). 
Because DUX4 downregulates MyoD in a manner that does 
not require its transcriptional activation domain,11,20,21 we also 
tested these compounds for potential relief of Myod1 repression 
(Fig. 5C). We purchased 10 of these compounds, including 
SHC161, a negative control determined to be a strong inhibitor 
of the Tet-on system, and tested this set of compounds first for 
effects on the induced DUX4 transcript (Fig. 5D). The Tet-on 
inhibitor control (SHC161) completely prevented DUX4 
expression, as expected. Of the others, four showed moderate 
Figure 2. Chemical series selected for follow-up. (A) Compound count vs core number. Red indicates compounds discovered in the 
previous screen; blue indicates compounds from the current screen. (B) Examples of representative cores.
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inhibition of the DUX4 transcript and five had no apparent 
effect on induced DUX4 expression. As an independent test of 
interference with the Tet-on system, we tested each compound 
over a dose series for inhibition of luciferase in the dox-
inducible iC2C12-luc cell line (Fig. 5E). From this set, three 
compounds (SHC351, 540, and 572) were found not to inhibit 
the Tet-on system at the highest dose tested. Finally, we evalu-
ated the potency of each of these repurchased compounds in the 
cell death protection assay. All three showed a dose-dependent 
inhibition of DUX4-mediated cytotoxicity (Fig. 5F).
We evaluated these three compounds for their perfor-
mance in our secondary screens, and found that all failed 
the relatively stringent viability cutoff (30% viability) that 
we set in the first screen, the repeat of the primary assay. 
Compound SHC540 came the closest to passing (0.28). 
Interestingly, it passed the i3T3-DUX4 screen. Of the three 
compounds, only SHC351 belonged to a defined chemical 
series (series 4); however, no other members of this chemi-
cal series had been identified as actives after secondary 
screening, from either the 44,000 or 160,000 screen.
Discussion
DUX4 is the prime therapeutic target in FSHD. The rapid cell 
death caused by DUX4 in C2C12 myoblasts facilitates this 
system for screening of small-molecule inhibitors of DUX4 
activity. A previous screen revealed that most compounds 
identified in this way were protective against oxidative stress,17 
which together with previous data on the pathological activity 
of DUX4,11 as well as oxidative stress readouts in patient myo-
blasts22 and in patients themselves,23 highlights the importance 
of this pathway in the cell death phenotype. Likewise, this 
screen of a much larger library necessitating a more stringent 
hit cutoff identified many inhibitors of oxidative stress–
induced cell death. In addition, two of the new oxidative stress 
protectors also protected against etoposide, a DNA damage–
inducing agent. This may be due to linkage of these two path-
ways or to a more general anti–cell death activity, although 
these compounds were inactive against a host of other death-
inducing insults. Of those compounds that did not act in any of 
the tested cell death pathways, it remained possible that some 
acted on DUX4 directly. However, of the 100 repurchased 
compounds, only 3 had activity against DUX4-induced Myo1g 
expression, indicating that the remainder were not active 
against DUX4 per se, but rather acted on downstream path-
ways. Outside of oxidative stress and DNA damage, what 
these pathways may be is unknown. For the three that did 
reduce Myo1g expression, they turned out to inhibit DUX4 
transcription and, indeed, transcription of a dox-induced green 
fluorescent protein transgene (Suppl. Fig. S1). These com-
pounds may be specific inhibitors of the Tet-on system, or 
more likely general inhibitors of transcription.
Figure 3. Protection from other cell death–inducing pathways. WT C2C12 cells were exposed to cell death–inducing drugs acting on 
various pathways in the presence of 5 µM purchased compounds. Viability (ATP content) is shown on the y axis. The first two points 
in each series represent controls: cells not treated with toxic agent, followed by cells treated with toxic agent plus DMSO alone. 
Compounds tested for protection are indicated from 1 to 46 on the x axis, error bars = SEM. A cutoff of three standard deviations 
above control (toxic agent + DMSO alone) is shown as a dotted red line. (A) Protection from 12.5 μM ABT-263. (B) Protection from 
0.0125 μM staurosporine. (C) Protection from 12.5 μM etoposide. (D) Protection from 12.5 μM ionomycin. (E) Protection from 25 
μM tBHP. (F) Protection from 2.5 μM tunicamycin.
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We prioritized compounds that were identified in chemi-
cal series for purchasing and validation. This assumes that 
structures of the desired activity are sufficiently frequent to 
be represented multiple times in a 200,000-compound 
library. However, it has become recognized that transcrip-
tion factors, perhaps because they generally do not have 
enzymatic active sites, are particularly difficult to target 
with small molecules, with some even labeling this class of 
protein essentially “undruggable.” With the recognition that 
our secondary screens severely refined the hit set, and that 
structures with the desired activity may be extremely rare, 
we went back to our 640-compound hit set and performed 
an alternative secondary screen, looking for compounds 
with activity against DUX4-mediated gene expression. 
Recognizing that such a screen would identify inhibitors of 
the Tet-on system, we then filtered the active compounds to 
remove those with activity against dox-induced DUX4 
mRNA. This eliminated the majority, leaving three interest-
ing compounds, discussed in more detail below.
Altogether, this study identified seven inhibitors of the 
Tet-on system: from the prioritized and purchased 100 com-
pounds, SHC40, 75, and 98, and from the rescreened 640 
phase II hit set, SHC161, 255, 452, and 634. There is no 
structural similarity within this set; however, three com-
pounds are classified as PAINS:24,25 SHC75 and 98 were 
recognized by the original filters18 and SHC634 because it 
has the potential to function as an irreversible inhibitor, 
which may react with cysteines.26
This left three compounds, SHC351, 540, and 572, 
which protected cells from toxicity of DUX4, did not inter-
fere with the Tet-on system, and prevented DUX4-mediated 
target gene upregulation. Looking at the structures of these 
compounds, one of these, SHC540, is classified as PAINS, 
and both SHC540 and 572 are predicted to be promiscuous 
toward targets using BADAPPLE (http://pasilla.health.
unm.edu/tomcat/badapple/badapple). SHC540 was origi-
nally developed as an antimalarial, but its mode of action is 
not documented in the literature.27 SHC351 is notably 
absent from the literature (SciFinder, 2016) though similar 
compounds have been reported as active against several 
diverse targets.28,29 Compound SHC572 is also absent from 
the published literature but, as is the case for all of these 
compounds, is available from compound vendors. Related 
compounds are known in the literature and have evidenced 
biological activity.30 Whether any of these compounds 
interact with DUX4 itself versus factors necessary for 
DUX4 activity is presently unknown. It will be important to 
test these compounds on FSHD myoblasts. Because none of 
these three compounds strongly prevented DUX4-mediated 
downregulation of Myod1, it seems unlikely that they are 
completely inactivating DUX4, but rather acting in a way 
that is specific to transcriptional activation, for example, by 
antagonizing a coactivator, or the interaction with a coacti-
vator. As much remains to be learned about mechanisms of 
transcriptional activation by DUX4, these compounds, 
which are commercially available, may be useful reagents 
to investigate this aspect of DUX4 function.
Figure 4. Transcriptional responses to DUX4 in the presence 
of selected repurchased compounds. (A) Expression levels of 
the DUX4 upregulated target gene, Myo1g, after dox addition 
in the presence of each compound. No dox and dox controls 
were tested in triplicate wells. No Tx (no compound, DMSO, or 
dox) was tested in duplicate wells. (B) Same analysis evaluating a 
DUX4 downregulated target gene, MyoD. (C) Activity of selected 
compounds on expression of the DUX4 transcript itself. Note 
that the compounds with the greatest effect on Myo1g and MyoD 
(40, 75, and 98) inhibited indirectly by preventing expression or 
accumulation of the DUX4 transcript. Compound 98 is shown in 
triplicate.
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